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Recent studies have highlighted the importance of eradication of human immunodeficiency
virus (HIV) and cure of acquired immunodeficiency syndrome (AIDS). However, a pivotal
point that the patient immunity controls HIV reactivation after highly active anti-retroviral
therapy [HAART or combination anti-retroviral therapy (cART)] remains less well addressed.
In spite of the fact that both innate and adaptive immunities are indispensable and numer-
ous cells participate in the anti-HIV immunity, memory CD4T-cells are indisputably the key
cells organizing all immune actions against HIV while being the targets of HIV. Here we
present a view and multidisciplinary approaches to HIV/AIDS eradication and cure. We aim
at memory CD4 T-cells, utilizing the stem cell properties of these cells to reprogram an
anti-HIV memory repertoire to eliminate the viral reservoir, toward achieving an AIDS-free
world.
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INTRODUCTION
Nothing stops an idea whose time has come. As in other scientific
discoveries, the time has come for human immunodeficiency virus
(HIV)/acquired immunodeficiency syndrome (AIDS) eradication
and cure, emerging from three decades of cutting edge research on
the HIV lifecycle, immune cell biology, and AIDS pathogenesis.
Additionally, a burgeoning study of stem cells has broadened our
knowledge of hematopoietic stem and progenitor cells (HSPCs)
as well as memory CD4 T-cells that have properties of stem cells,
to elucidate their decisive roles in the battle of modern medi-
cine against HIV infection. We specifically address studies and
approaches that focus on functional CD4 T-cell helped immune
memory, a foundation and the mechanism of patient anti-HIV
immunity, vaccination, a cure and a functional cure of AIDS after
HAART.
A TRINITY OF HIV/AIDS ERADICATION AND CURE
A trinity of strategies on HIV/AIDS eradication and cure stems
from the three theories or three scientific achievements: (1) defin-
ing CD4 T-cells in HIV/AIDS pathogenesis and immunity, (2)
developing highly active anti-retroviral therapy to stop HIV repli-
cation; and (3) studying of ancient human endogenous retro-
viruses (HERVs) in the human genome, of which HIV is a modern
example.
First, as in other viral infections, CD4 T-cells, specifically mem-
ory CD4 T-cells, govern the antiviral immunity against HIV infec-
tion. Whereas they commit themselves to antiviral immunity, CD4
T-cells, specifically memory CD4 T-cells, are the target cells of
HIV. It is the dual role of memory CD4 T-cells in HIV infection
that lays down the unique challenge for HIV/AIDS eradication
and cure. Secondly, HAART blocks HIV replication in patients,
controls viremia and viral transmission to people, which opens
avenues to reconstitute patient HIV-specific immunity. However,
no HAART so far has developed to stop the HIV provirus func-
tion. Finally, the research on HERVs shows that these viruses are
the close relatives of HIV, and are present in the human genome
without harm for generations. Harnessing the power of host cells
employing to silence foreign DNA in the genome ultimately leads
to a control of HIV provirus activity and therefore control of the
viral reservoir.
In short, due to the dual role in HIV infection and anti-HIV
immunity, memory CD4 T-cells have a dual role in control of viral
reservoir and reconstitution of anti-HIV immunity after HAART.
More than 28 approved drugs have been developed to target five
different viral proteins in the HIV lifecycle, plus one targeting cel-
lular protein CCR5 but none targeting on provirus to stop the viral
RNA transcription (Table 1A). Besides HAART, immune therapies
have been developed to reconstitute anti-HIV immunity, in which
eight drugs are used in clinical trials, including bio-molecules for
gene therapy and vaccine treatment (Table 1B). Despite all the
anti-retroviral and immune treatments, reconstitution of patient
anti-HIV immunity and control of the HIV reservoir remain elu-
sive. The mechanisms that the host cell employs to permanently
silence HERVs are explored, but little is known about how to uti-
lize these heritable epigenetic machineries to silence HIV provirus
and control HIV reservoirs in patients (1–15).
THE ROLE OF MEMORY CD4 T-CELLS
The key player in AIDS pathogenesis and cure is the memory CD4
T-cells. These cells are predominantly quiescent but are capable
of intermittent self-renewal and long-term survival, meaning that
these cells have stem cell like properties of HSPCs at the cell-cycle
control, self-renewal, asymmetric division, and differentiation into
effector cells (16–32). Let us briefly view the mechanisms, which
memory CD4 T-cells employ to play the pivotal roles in eradication
of HIV and cure of AIDS.
Upon naïve CD4 T-cells meeting a pathogen, in this case, the
HIV, these cells differentiate into antigen specific effector cells.
Some of them die due to the viral infection or their biological
destinies, but some survive and become memory cells and fur-
ther develop into secondary effector cells. When encountering
HIV again, these antigen specific T-memory cells, in this case HIV
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Table 1 | Anti-retroviral and immunotherapeutic drugs used in HIV eradication andAIDS cure. (A) More than 28 approved drugs target five different
viral proteins in the HIV lifecycle, plus one targeting the cellular protein CCR5 but none targeting at provirus transcription. (B) Immunotherapies are
developed in addition to HAART to reconstitute anti-HIV immunity, in which eight drugs are being used in clinical trials, including the bio-molecules for
gene and vaccine therapies. Although a decreased viral load and an increased CD4 T-cell number are reported specifically after vaccine treatment in
patients with or without cART, the results of immunotherapy approaches remain in phase I or II, and to be confirmed by phase III trials for their efficacy,
side effects and safety.
A B
HAART block multiple steps in HIV lifecycle Immune-based therapies
Binding and Fusion Maraviroc, Fuzeon . . . Aralen (Chloroquine phosphate)
Reverse Transcription Emtriva, Edurant . . . DermaVir (therapeutic vaccine)
Integration
Transcription
Raltegravir, Dolutegravir . . . Interleukin-7 (IL-7)
Lexgenleucel-T (VRX-496; gene therapy)
Assembly Aptivus, Ritonavir . . . Plaquenil (hydroxychloroquine)
Budding Bevirimat Proleukin (aldesleukin, Interleukin-2, or IL-2)
SB-728-T (gene therapy)
Vacc-4x, FIT-06 . . . (therapeutic vaccine)
specific, replicate and differentiate into the secondary effector cells
(Figures 1A–C). The HIV specific effector cells, specifically mem-
ory CD4 T-cells, play decisive roles not only in anti-HIV immunity
(33–35) but also in AIDS pathogenesis, since these cells govern
functions of both CD8-cells and B-cells, regulate both cellular and
humoral immunities, thereby determine the prognosis of AIDS
(Figure 1B).
Memory CD4 T-cells are heterogenous and proposed to exist in
at least three classes dubbed central memory (TCM), transitional
memory (TTM), and effector memory (TEM) T-cells, plus previ-
ously identified Th1 and Th2 memory cells and recently defined
Th17 memory cells (16–32). Among them, secondary effector cells
of Th17 are the key players in mucosal immunity yet these cells
are unable to completely recover from the early HIV destruction
even after successful HAART (36, 37).
Likewise, there are memory CD8 T-cells. Differing from mem-
ory CD4 T-cells, however, generation of functional CD8 T-cell
memory requires the help of CD4 T-cells. A defective CD8 T-cell
memory following acute infection without CD4 T-cell help has
been identified in numerous animal model studies. Many efforts
are complied to rescue the CD4-unhelped CD8 T-cell memory to
restore the viral specific immunity (38–45). Scarce studies, how-
ever, have been conducted on CD4-unhelped CD8 T-cell memory
in HIV patients, who have an inverted ratio of CD4/CD8 and a
signature defective CD4-unhelped CD8 T-cell memory following
the HIV acute infection (46–53). Considering that vaccine strate-
gies are built on the immune cell memory function and CD8 T-cell
memory needs the help of CD4 T-cells, elucidation of how CD4
T-cells program CD8 memory or how CD4 T-cell is required for
the long-term maintenance of CD8 memory T-cell numbers and
functions will add great value to reconstitution of patient anti-
HIV immunity (38–53). Moreover, recent studies show that CD4
T-cells control the proliferation, accumulation, and activation of
natural killer (NK) cells (54, 55). HIV induced loss of CD4 T-
cells plus an impaired CD4 T-cell activity appear to contribute
to progression of liver fibrosis in patients co-infected with HIV
and hepatitis C virus (HCV) (56). In light of these results, no
matter what mechanism of CD8 T-cells or NK cells employ to kill
HIV, it is clear that memory CD4 T-cells act as a commander in
chief in launching and orchestrating the immunity against HIV
(Figure 1C). Without this leadership, small local battles may be
won, but the whole war is lost.
We and others have focused on studying the repertoire function
of memory CD4 T-cells, that is the function of a group of mem-
ory CD4 T-cells governing the anti-HIV immunity. We examined
the patterns and the courses of surviving memory CD4 T-cells
in which they develop into effector cells and their function with
memory CD8 T-cells after the viremia. We believe that the reper-
toires of memory CD4 T-cells after the HIV attack decide the
anti-HIV immunity and the status of HIV/AIDS pathogenesis in
individuals (16–32). If a close to normal repertoire of memory
CD4 T-cells survive after the early viremia, meaning the first and
second viremia (57–60), the HIV replication can be controlled by
the host immunity with or without HAART. In most HIV infec-
tions, however, the repertoire of memory CD4 T-cells is damaged
and destroyed. This not only results in HIV/AIDS pathogenesis,
but also a big challenge in reconstitution of anti-HIV immunity.
The loss of immune memory repertoires of CD4 T-cell also sets
the biggest hurdle to the development of HIV/AIDS vaccine since
a damaged CD4 T-cell memory and a CD4 T-cell unhelped CD8
T-cell memory can only lead to a defective vaccine and an aborted
vaccination.
Memory CD4 T-cells have a pivotal role in HIV/AIDS eradica-
tion and cure. Not only are these cells the key cells in HIV infection
and immunity, but these cells also have the stemness properties of
HSPCs. The asymmetric dividing of memory CD4 T-cells pro-
vides the long-living memory cells serving as a major source of
HIV reservoir on the one hand, and on the other hand, provides
the short living effector cells serving as the targets of HIV replica-
tion. The stemness properties of memory CD4 T-cells stem from
HSPCs. What is the role of HSPCs in HIV/AIDS eradication and
cure? We and others have studied HIV infection of HSPCs. We
have found that HSPCs are resistant to HIV infection, despite that
other bone marrow cells, including blood lineage progenitor cells,
Frontiers in Immunology | HIV and AIDS October 2013 | Volume 4 | Article 337 | 2
Zhang and Crumpacker Strategies for HIV/AIDS cure
FIGURE 1 | Memory CD4T-cells in anti-HIV immunity. (A) Naïve CD4
T-cells are derived from CD4 lineage progenitors. Upon meeting a pathogen,
such as HIV, naïve CD4 T-cells differentiate into antigen specific effector
cells. Some of them die due to the viral infection or their biological
destinies, whereas some of them survive and become memory cells and
further develop into secondary effector cells. These memory cells retain the
stem cell properties of asymmetric division, self-renewal, and
differentiation into effector cells. (B)When encountering HIV again, these
antigen specific memory T-cells, in this case HIV specific, repeat the
process in (A), and majority of effector cells die but some of memory cells
sustain to continue the cycle. In general, the earlier the application of
HAART is, the more memory cells preserve or survive. (C)The memory
CD4 T-cells act as a commander in chief, in the leadership position for
launching anti-HIV immunity as these cells govern functions of both
CD8-cells and B-cells, regulate both cellular and humoral immunities, by
which determine the prognosis of AIDS.
are accessible to HIV infection (61–66). At the level of HIV/AIDS
eradication and cure, however, the techniques and methodologies
for studying of HSPCs should be utilized to study memory CD4
T-cells, peculiarly for translational research and multidisciplinary
collaborative studies.
Of note, recent studies reveal that memory CD4 T-cells pref-
erentially reside and rest in the bone marrow, and virus-specific
memory CD4 T-cells are abundant in unexposed adults (67, 68).
Accordingly, HIV patients are capable of rebuilding HIV specific
immunity via these abundant memory CD4 T-cells after HAART,
responding to HIV as a novel pathogen to take the second chance
reestablishing anti-HIV immunity from an abundant in vivo pool
of memory CD4 T-cells (16–32,67,68). Tackling the second chance
to rebuild patient immunity against HIV after HAART is the prime
goal to achieving an AIDS-free world.
HERVs AND HIV PROVIRUS
A rationale for urging that HIV/AIDS can be eradicated and cured
is further backed up by the third theory: the ancient HERVs are
present in the human genome for many generations without harm.
HERVs are the close relatives of HIV, which are kept silenced per-
manently in the human genome via cellular epigenetic machineries
(1–11). The past and current studies have revealed that the epige-
netic regulation is the prime mechanism which host cell employs
to protect its genome integrity against the invasion of foreign DNA
including HIV DNA (the provirus) (1–11, 15, 69–71).
Epigenetic regulation consists of DNA methylation at CpG
dinucleotides, covalent modification of histone proteins in chro-
mosomes, and interplay of non-coding RNAs (ncRNAs) in the
genome. Among them, DNA methylation is the best-understood
and most thoroughly studied epigenetic regulation, of which
DNA methyltransferase 3b (DNMT3b) is the main enzyme for
de novo DNA methylation. Epigenetic regulation is fast, potent,
heritable, and it changes the gene expression at a transcrip-
tional level without changing of DNA sequences, the very step
in HIV lifecycle that HAART is off target (Table 1). While no
HAART regimen to date silences HIV proviral gene transcrip-
tion, DNA methylation is, however, a showcase in silencing gene
expression of HERVs included HIV in the human genome and
also in controlling of retroviral diseases in animal model studies
(1–11, 15, 69–71). Note that with HAART, HIV is kept as non-
virulent but remains in the reservoir, which consists mainly of
memory CD4 T-cells (72–79). Epigenetic regulation is an evo-
lutionarily developed mechanism with a signature of silencing
foreign DNA expression, like blocking the transcription of HIV
provirus, while maintaining cellular gene function. Considering
the double role of memory CD4 T-cells in HIV immunity and
infection, we believe utilizing epigenetic regulation to silence HIV
in memory CD4 T-cells is a win–win strategy, which silences HIV
without hurting cellular gene expression, and stops HIV provirus
without losing lives of memory CD4 T-cells who intend to be
long-memory, long-living, and everlasting to patient HIV-specific
immunity.
It is widely accepted that when exposed to antigenic stimu-
lus, the normal immune system mounts an appropriate response
and then returns to relative quiescence after clearing the anti-
gen. Memory CD4 T-cells govern this process by returning to a
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quiescent status (G0/G1), which allows the innate and adaptive
immune systems to go back into a reset or surveillance state. HIV
disrupts this balance by provoking chronic immune activation,
cytokine elaboration, and ultimately alteration of the microenvi-
ronment of the immune system. HAART restores the quiescence
by blocking HIV replication without silencing the provirus in
host cells. One can promote an immune activation from the
immune quiescence after HAART, or one can utilize the intrin-
sic cellular epigenetic machineries to preserve the quiescence
induced by HAART for these memory CD4 T-cells. Consider-
ing the rapid progress in studying of immune cells and their
niches, we can harness the intrinsic epigenetic machineries to
silence provirus activity in the memory CD4 T-cells and sequen-
tially promote the CD4 T-cell helped CD8 T-cell memory. We
consider the epigenetically regulated memory CD4 T-cells and
the CD4 T-cell helped CD8 T-cell function to be the founda-
tion of an AIDS cure, either sterile or functional. Specifically,
one can utilize DNA hypermethylation to permanently silence
HIV provirus in memory CD4 T-cells akin to silencing HERVs,
and such strategy is being studied and developed (1–11, 15,
69–71, 80).
CELLULAR FACTORS IN HIV/AIDS ERADICATION AND CURE
Cellular factors TRIM5α, APOBEC3G, SAMHD1, etc. are stud-
ied by many investigators to define the effects of these proteins
in HIV infection and AIDS cure. P21Waf1Cip1Sdi1 (p21) is one of
them. P21 is a cyclin dependent kinase inhibitor regulating cell
cycle, particularly in blood cells. We study p21 because p21 plays
an indispensable role in immune cell quiescence, differentiation,
senescence, and apoptosis, in addition to the role of this single
cell checkpoint protein playing in HSPCs resistance to HIV infec-
tion (61–64, 81–90). Importantly, p21 dictates cell-cycle status of
HSPCs whereas memory CD4 T-cells have the properties of HSPCs
(16–32). Based on memory CD4 T-cells playing a dual role in
reconstitution of anti-HIV immunity and control of HIV reser-
voir after HAART, revelation of the mechanism of p21 in cell-cycle
control, turnover, senescence, and apoptosis of memory CD4 T-
cells is pivotal for reprograming patient HIV-specific immunity
and eliminating the viral reservoir.
Molecularly, p21 is activated by damage to cellular DNA, via p53
dependent and in-dependent pathways. After p21 activation, there
are two possible outcomes for blood cells: being quiescent and
arresting in G1 phase, or being senescent and going into apoptosis
(81–90). The former, on the one hand, is the base of HIV reser-
voir, and the latter, on the other hand, is the platform to get rid
of this reservoir. Therefore, p21 is imperatively a focus point not
only in understanding of memory CD4 T-cell differentiation and
renewal, but also in apoptosis and turnover, all directly affecting
the dimension of HIV reservoir in vivo (61–68, 72–79, 81–94).
We have studied p21 in HIV infection since 2002 (22, 61–64).
At the beginning, we investigated the function of p21 in HSPCs
after HIV infection. Today, we propose to continue to examine the
role of p21 in activation, senescence, and apoptosis of immune
cells, in order to restore a memory CD4 T-cell repertoire to recon-
stitute, or in a more accurate term, to reprogram the CD4 T-cell
helped CD8 T-cell and B-cell immune memories to rebuild patient
HIV-specific immunity.
In our previous studies, we have demonstrated that p21 plays
a central role in HSPCs resisting HIV infection. The p21 medi-
ated resistance to HIV infection in blood stem and progenitor
cells occurs at the viral integration step, by which makes HSPCs
a sanctuary in resisting HIV provirus formation (61–63). Our
recent studies further showed that p21 directly bound to HIV
long terminal repeat (LTR) and integrase (IN), respectively (data
not shown).
To summarize, our molecular studies show that p21 blocks
HIV infection in HSPCs at the viral integration step. P21 directly
interacted with LTR and IN, indicating that blood cells or the
immune cells have an innate resistance against retroviral infec-
tion at the level of preventing viral DNA integration. Additionally,
other investigators have found that p21 inhibits HIV infection
in macrophages and CD4 T-cells, respectively, by different cel-
lular mechanisms and pathways (91–94). From study of p21,
we realize that as a principle of immunotherapy and vaccina-
tion, the induced immunity has to be efficient enough to target
or to block a key step in the viral lifecycle. For a retrovirus
like HIV, the key steps include: (1) to stop HIV integration so
the provirus cannot be formed in the host genome, (2) to stop
the transcription after the provirus formation so the viral DNA
is kept silent until the cell senescence or apoptosis. So far, no
drug in HAART targets the second step. P21, however, appears
to have functions at both these steps. Moreover, p21 is a cellu-
lar factor having a tumor suppressor function, which makes p21
a good candidate to synergistically regulate the immunity with
either chemotherapy or HAART in AIDS patients with or without
tumors.
MOLECULAR AND CELLULAR STRATEGIES TACKLING HIV
RESERVOIR
Due to the stem cell like properties, not only are memory CD4 T-
cells the key cells to reconstituting patient anti-HIV immunity, but
also a major HIV reservoir. Genetic and epigenetic approaches are
being developed to eliminate HIV reservoirs, including targeted
genome cleavage by zinc finger nucleases (ZFNs) (12–14), and epi-
genetic modulations such as histone deacetylation, histone methy-
lation, and DNA methylation (1–11, 15, 69–71). As previously
stated, the difference between genetic and epigenetic approaches
on eradicating HIV infection is that the former changes the host
cell genome, the blue print, but the later does not. Epigenetic regu-
lations control the gene expression without changing the host cell
DNA sequences.
The targeted genome cleavage utilizing ZFNs has shown success
in CCR5 knockout T-cells isolated from HIV patients to protect
these lymphocytes from HIV infection. These approaches are now
moving into the clinic with CCR5-specific ZFNs being used to dis-
rupt CCR5 in autologous T-cells transplanted into HIV-infected
patients (clinicaltrials.gov, NCT00842634, NCT01044654). As for
targeting and cleaving regions within latent HIV genomes, how-
ever, ZFNs based approaches are still in development. The big
challenge is the accessibility of ZFNs to HIV DNA, due to the
formation of repressive chromatin at the HIV promoter, includ-
ing loss of activating histone modifications, presence of repressive
modifications, and presence of DNA methylation that has been
implicated in HIV latency (1–11, 15, 69–71). The recognition and
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cleavage of ZFNs on HIV DNA may further be compromised by
the presence of heterochromatin and possibly nucleosome posi-
tioning (15, 69–71). In sum, the efficacy of approaches like ZFNs
in control of the viral reservoir depends on the epigenetic status
of HIV DNA in the human genome.
Regarding the implementation of epigenetic approaches to
eradicate the viral reservoir, the most widely discussed method
is to using histone deactylase inhibitors such as suberoylanilide
hydroxamic acid (SAHA) to reverse latency in resting CD4 T-cells
with the assumption that the cells will then die from viral cyto-
pathic effects or be lysed by host cytolytic T-cells after disruption
of the latency (95–99). Current findings, however, show that the
reactivation or latency disruption might not be sufficient to erad-
icate the HIV although some of these inhibitors are advanced to
clinical trials (95–99).
Strategies like stem cell transplantation, therapeutic vaccina-
tion, and increasing the concentrations anti-retroviral compounds
in the sanctuary sites of the viral reservoir have been applied
in eradication of HIV reservoirs. Particularly, multiple means to
increase drug concentrations in sanctuary sites are being inves-
tigated, for improving the efficacy of HAART, including modifi-
cation of currently utilized drugs, blockade of transporters and
enzymes that affect drug metabolism and pharmacokinetics, and
the local drug administration (100, 101).
Despite all above approaches, the inability of the immune
system to recognize cells harboring latent virus and inability to
eliminate cells actively producing virus remain the biggest chal-
lenge toward HIV/AIDS eradication and cure. Investigators look
at new strategies to unravel the virus-host interactions that lead to
viral persistent infection and memory CD4 T-cell quiescence, and
discuss the rationale for combination of novel treatment strategies
with available anti-retroviral treatment options to cure HIV. One
of the strategies, which is used in cancer immunotherapy to kill
cancer cells by bio-engineered mesenchymal stem cells (MSC), is
in development and can apply to eliminate quiescent memory CD4
T-cells harboring HIV. This strategy aims to attack viral reservoirs
throughout the body, including the central nervous system, gut-
associated lymphoid tissue, lymph nodes, and tissue macrophages,
since MSC reside not only in bone marrow but also in other
tissues, and differentiate into multiple stromal cells throughout
the human body. MSC periodically circulate in blood, tend to
lodge in lymphatic tissues and further divide into progeny cells
(102–104). Bio-engineered MSC can approach the compartments
that HAART cannot reach, not only eliminating viral reservoir
but also restoring a niche that replenishes HIV-specific memory
CD4 T-cells and executes the HIV-specific memory, function, and
immunity.
As shown in Figure 2, MSC bearing an LTR-diphtheria toxin
(DT) gene can be activated after exposure to HIV Tat, and express
DT to kill the cells expressing Tat (105). The MSC bearing LTR-DT
act as a time bomb, to die and explode, killing cells of active HIV
infection with Tat expression. These MSC are not only timed and
directed, but also outnumbered their enemies, waiting patiently
to kill the enemy cells with a potency not regarding their own
survival. Such stem cell based therapy reinforces HIV-specific
immune responses by nourishing memory CD4 T-cells while elim-
inating cells with active HIV infection, helping to reach the goal of
FIGURE 2 | A stem cell based treatment. In addition to hematopoietic
stem cell transplant, other stem cells, such as MSC, can be used in
HIV/AIDS eradication and cure via relatively easy cellular source and
process. The modified MSC aim at compartments refractory to HAART, and
this strategy is derived from the cell-based therapy killing cancer cells by
pro-drug delivery with MSC. After transduction of LTR-DT gene and
interaction with cells infected by HIV expressing Tat, these MSC are
activated and diphtheria toxins (DT) are generated. The toxin kills the
infected CD4 T-cells and nearby cells included MSC producing the toxin, by
which eliminates the HIV-infected cells and the HIV reservoir.
eradication of viral reservoirs or the alternative aim of a functional
cure for HIV.
Furthermore, in contrast to activating quiescent HIV and cells
by histone deactylase inhibitors like SAHA, another innovative
strategy is developed to permanently silence but not to activate
the integrated HIV and prevent the spread of infection, in line
with the results in studying of HERVs (Figure 3). One of these
studies reports that a chimerical protein IN3b, consisted of a HIV-
1 IN domain recognizing the HIV LTR and the catalytic domain of
DNMT3b, decreases LTR-associated HIV genome expression and
HIV replication, to cause the long-term silencing of HIV repli-
cation by permanently silencing the HIV promoter in the cell
genome (80).
Human immunodeficiency virus is akin to HERVs that are
methylated in the human genome and passed for generations
without causing retroviral diseases (1–11, 15, 69–71). A hyper-
methylation at the DNA sequence of HERVs and silencing of viral
gene expression have been recognized as the underpinning mech-
anisms (1–11, 15, 69–71). Thus, a targeted hypermethylation at
the HIV promoter leads to and results in a sterile blocking of
HIV RNA expression, mimicking what occurs to HERVs. Bio-
logically, an initial DNA methylation is followed by a histone
modification resulting in the secondary epigenetic modifications
at the chromosomal level. The primary and secondary modifica-
tions will permanently lock the HIV promoter, forcing the HIV
to become another endogenous retrovirus in the human genome.
This process significantly differs from an assumed HIV latency
that occurs at a histone level, responding to numerous stimuli and
not being stable or heritable (1–11, 15, 69–71).
To sum up, although HAART effectively controls the viremia
and viral transmission, the patient HIV-specific immunity and
the viral reservoir remain as two big hurdles in HIV/AIDS eradi-
cation and cure. For an AIDS cure or a functional cure of which
host and virus co-exist for a long term in the absence of toxic
and costly drugs, the patient HIV-specific immunity after HAART
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FIGURE 3 | Silencing HIV reservoir via epigenetic machineries.
(A) Methylated HERVs are passed for generations without causing retroviral
diseases, and a targeted hypermethylation at the DNA sequence of HERVs
has been recognized to be the mechanism silencing gene expression of
ancient endogenous retroviruses in the human genome (1–11). (B) HIV is a
modern example of HERVs. A targeted hypermethylation at the HIV
promoter will be possible to genetically and sterilely block HIV RNA
expression, mimicking what occurs to HERVs. DNMT3b is the prime
enzyme catalyzing the transfer of methyl groups to cytosines of a targeted
gene to silence the gene expression in the human genome, specifically to
endogenous retroviruses and transposons. LTR contains the most
conserved DNA sequence in a latent HIV. DNMT3b-LTR binds to the proviral
LTR by base pair affinity, in a time of either RNA transcription or DNA
semi-conservative replication. The bio-molecule binding to the HIV LTR leads
to a heritable, stable DNA hypermethylation at the HIV promoter (1–11, 15,
69–71, 80).
is indisputably a key (46, 106, 107). This is a matter of fun-
damental principle in modern medicine regarding the roles of
human immunity vs. chemical compounds in a human body: who
has the final say on eradication of HIV and cure of AIDS? Can
HAART replace patient immunity to cure AIDS? Can we develop
an HIV vaccine without immune cell memory? Finally, what have
we learned from cancer therapy, and is there a connection in lack
of antigen specific immune memory between AIDS and cancer
patients after the respective chemotherapies? Others have pro-
vided answers and approaches toward the HIV/AIDS eradication
and cure, and we add more to this as follows (Figure 4).
CONCLUDING REMARKS
Retrospectively, infectious diseases have been cured for only one
reason – human immunity controls the replication of, and/or gets
rid of the pathogen, with or without anti-microbial drugs. In spite
of the help of anti-microbial compounds, it is the human immune
system that has the final say on a disease being cured or not. Both
innate and adaptive immunities are indispensable, and numerous
immune cells take part in and each plays a pivotal role, but memory
CD4 T-cells have an undisputable role as the commander in chief
to organize all immune actions against an invading pathogen (16–
32, 38–60). The function of memory CD4 T-cells is, undoubtedly,
the foundation of both adaptive immunity and its branch applied
to medical science, the vaccine and vaccination.
Being in an era of modern medicine after the human genome
project, in the center of burgeoning study on stem cells and trans-
lational therapies, after three decades of intensive research on the
lifecycle of HIV and pathology of AIDS, with a team effort of
investigators in multiple disciplines and cross-fields, similar to
others, we present our opinions and approaches toward achiev-
ing an AIDS-free world that are derived from our two decades of
studying HIV replication, immune cell biology, and AIDS pathol-
ogy. We have reviewed how we will work from a trinity of strategies
to eradicate HIV and cure AIDS, to reprogram the immune reper-
toire function of memory CD4 T-cells and reconstitute patient
FIGURE 4 | A trinity of HIV eradication and AIDS cure. Strategies and
approaches stem from the three achievements in the field of studying
HIV/AIDS. Each alone, however, cannot achieve the goal toward an
AIDS-free world. HAART decreases the HIV DNA thus increases the
memory CD4 T-cell function. Increased memory T-cell function in turn
controls the activity of viral DNA therefore increases the efficacy of HAART.
Approaches with impacts on the triad, such as modulating memory CD4
T-cell turnover, eliminating HIV reservoir, and silencing HIV DNA, ultimately
lead to reprogram memory CD4 T-cell repertoire and patient anti-HIV
immunity. An AIDS-free world will be built on patient immunity against HIV,
regulated by memory CD4 T-cells endowed with long living, self-renewing,
and differentiating into antigen specific effector cells to control HIV provirus
activation.
anti-HIV immunity to cure AIDS with or without HAART. Gener-
ation of effective anti-HIV vaccines has been a particularly difficult
task. Therefore, attempts to cure AIDS via early administration
of anti-retroviral therapies maybe in the long run a more suc-
cessful and rewarding strategy. To conclude, utilizing powers of
HAART, either by developing compounds or bio-molecules to
stop provirus transcription or reprograming memory CD4 T-cells
to reconstitute patient HIV-specific immunity, we can pave a road
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for generating effective AIDS vaccines; by deciphering the mech-
anisms of memory CD4 T-cell guided immunity, we may open
a door reconstituting patient immunity against not only cancer
but AIDS.
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